Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
27 /100
MEDIUM RISK
Score updated Oct 13, 2026

JANX — Janux Therapeutics, Inc. Dilution Risk Tracker

Track JANX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track JANX — Get alerts when the score changes →

As of October 13, 2026, Janux Therapeutics, Inc. (JANX) has a DilutionWatch DilutionScore of 27/100, rated MEDIUM dilution risk. Janux Therapeutics, Inc. has a market capitalization of $1.11B, 61.14M shares outstanding, 193 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
0
📊 Float Risk
30
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for JANX.
🔔 Track JANX — Get forecast alerts →

Market Data

Market Cap$1.11B
Shares Outstanding61.14M
Float39.19M
Cash$970.91M
Debt$21.57M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore27/100DilutionWatch score record
Shares Outstanding61.14MVerified float table or market cache
Public Float39.19MVerified float table or market cache
Market Cap$1.11BMarket data cache
Cash Runway200.5 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 2.

Recent SEC source mix: 3 1, 4 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 9.0% shares (2026Q1 vs prior)
193 institutional holders · 70.52M shares
#1 RA CAPITAL MANAGEMENT, L.P. 11.19M shares
#2 JANUS HENDERSON GROUP PLC 8.39M shares
#3 BlackRock, Inc. 5.43M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest5.68M
Days to Cover5.9
% of Float14.5%
FINRA data as of Sep 30, 2026

Recent SEC Activity

3 FORM3 2026-02-04
4 INSIDER TRANSACTION 2026-02-04
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual JANX Dilution Snapshot

Janux Therapeutics, Inc. (JANX) has a DilutionScore of 27/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

JANX's DilutionScore has held steady at 27/100 (Medium risk) for 89 consecutive days across the tracked period.

Period Score Risk Level Duration
Jul 16 – Oct 13, 202627/100MEDIUM89 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

JANX shares outstanding have increased 0.0% from 60.96M (May 2026) to 60.98M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 31, 202660.98M39.19M▼ 0.01%
May 19, 202660.98M39.20M▲ 1.12%
May 16, 202660.98M38.76M▲ 0.02%
May 10, 202660.98M38.76M▲ 0.37%
May 03, 202660.96M38.61M▼ 7.36%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track JANX Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment JANX files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking JANX — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for JANX
JANX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.